

## **Supplementary Figure 2**

Bevacizumab reduces the growth rate constants of renal carcinomas. A novel algorithm suggests early discontinuation of bevacizumab resulted in a lack of survival advantage.


Wilfred D. Stein<sup>1,2</sup>

James Yang<sup>3</sup>

Susan E. Bates<sup>1</sup>







Tito Fojo<sup>1,4</sup>

# Patients Randomized to High Dose Bevacizumab




# Patients Randomized to High Dose Bevacacizumab

Tumor quantity (Starting quantity arbitrarily set at 100%)




Weeks on study

# Patients Randomized to High Dose Bevacizumab









# Patients Randomized to High Dose Bevacizumab



# Patients Randomized to High Dose Bevacizumab







Tumor quantity (Starting quantity arbitrarily set at 100%)



Weeks on study

# Patients Randomized to High Dose Bevacacizumab

Tumor quantity (Starting quantity arbitrarily set at 100%)



Weeks on study